All In Biotech

NDA 214155 · Melinta Therap

Kimyrsa

Oritavancin Diphosphate · Intravenous

Last checked: Nov 20, 2026Latest source record: Apr 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2021

Mar 12, 2021

Approved uses

1

Original approval plus efficacy supplements

Registered trials

7

2 Phase 3, 0 recruiting

FAERS reports

297

98 serious, 5 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Dec 18, 2025.

KIMYRSA is a lipoglycopeptide antibacterial drug indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of KIMYRSA and other antibacterial drugs, KIMYRSA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) 1.1 Acute Bacterial Skin and Skin Structure Infections KIMYRSA ® is indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant isolates), Streptococcus pyogenes , Streptococcus agalactiae , Streptococcus dysgalactiae , Streptococcus anginosus group (includes S. anginosus , S. intermedius , and S. constellatus ), and Enterococcus faecalis (vancomycin-susceptible isolates only). 1.2 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of KIMYRSA and other antibacterial drugs, KIMYRSA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Mechanism: Oritavancin is an antibacterial drug [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 12, 2021 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabel
1 products under this application
  • KIMYRSA · ORITAVANCIN DIPHOSPHATE EQ 1.2GM BASE/VIAL · POWDER, INTRAVENOUS · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Oritavancin Diphosphate" as an intervention, any sponsor and status, largest first.

All 7 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • multiple use of single-use product109
  • chills92
  • infusion related reaction67
  • off label use49
  • back pain42
  • dyspnoea38
  • pruritus37
  • tremor36
  • flushing35
  • nausea35
  • rash25
  • chest pain24

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
20201
20212
202252
2023144
202453
202535
20269

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Kimyrsa (Oritavancin Diphosphate)

2024 spending

$649K

Beneficiaries

62

119 claims

Per beneficiary

$10,474

$5,194.98 per unit

View as table
YearSpending
2020$0
2021$0
2022$627,045
2023$1,027,040
2024$649,372

Part B: Kimyrsa (Oritavancin Diphosphate) · HCPCS J2406

2024 spending

$8.6M

Beneficiaries

1,154

1,743 claims

Per beneficiary

$7,455

2024 ASP limit $41.56 per unit

View as table
YearSpending
2020$0
2021$125,805
2022$6,048,696
2023$8,393,711
2024$8,603,060

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Melinta Therap

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.